Biopharma business a key driver for Lonza in 2016

By Gareth Macdonald contact

- Last updated on GMT

iStock/nan_bkk
iStock/nan_bkk

Related tags: Mammalian cell culture, Biotechnology

Lonza has cited demand for mammalian cell culture manufacturing and contracts signed with cell and gene therapy as key drivers in 2016.

The Swiss life sciences supplier’s pharma & biotech segment saw revenue increased 15.9% in 2016 to CHF1.85bn ($1.84bn) with core earning growing 40.8% to CHF400m.

Lonza said the gains were driven by strong momentum in its mammalian manufacturing business – which produces biopharmaceuticals for drug industry customers - and a “by a significant upward trend in all other technologies and modalities.”

The firm also highlighted manufacturing contracts with Kodiak Sciences, bluebird bio and Clovis Oncology signed during the year.

Company-wide revenues increased 8.7% to CHF4.13bn while earning grew 24.2% to CHF651m.

Lonza will hold its conference call later today.

Related topics: Markets & Regulations

Related news

Show more

Follow us

Products

View more

Webinars